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Abstract
Hyperphosphorylation of the microtubule-associated protein tau is a significant determinant in AD
(Alzheimer’s disease), where it is associated with disrupted axonal transport and probably causes synaptic
dysfunction. Although less well studied, hyperphosphorylation has been observed in prion disease. We have
investigated the expression of hyperphosphorylated tau in the hippocampus of mice infected with the ME7
prion agent. In ME7-infected animals, there is a selective loss of CA1 synapse, first discernable at 13 weeks
of disease. There is a potential that dysfunctional axonal transport contributes to this synaptopathy. Thus
investigating hyperphosphorylated tau that is dysfunctional in AD could illuminate whether and how they
are significant in prion disease. We observed no differences in the levels of phosphorylated tau (using MC1,
PHF-1 and CP13 antibodies) in detergent-soluble and detergent-insoluble fractions extracted from ME7-
and NBH- (normal brain homogenate) treated animals across disease. In contrast, we observed an increase
in phospho-tau staining for several epitopes using immunohistochemistry in ME7-infected hippocampal
sections. Although the changes were not of the magnitude seen in AD tissue, clear differences for several
phospho-tau species were seen in the CA1 and CA3 of ME7-treated animals (pSer199−202>pSer214>PHF-1
antibody). Temporally, these changes were restricted to animals at 20 weeks and none of the disease-
related staining was associated with the axons or dendrites that hold CA1 synapses. These findings suggest
that phosphorylation of tau at the epitopes examined does not underpin the early synaptic dysfunction.
These data suggest that the changes in tau phosphorylation recorded here and observed by others relate to
end-stage prion pathology when early dysfunctions have progressed to overt neuronal loss.
Introduction
Active bi-directional transportation of organelles along the
axon between the cell body and the synapse is essential for
neuronal signalling and survival [1]. Synaptic components,
and their precursors, are transported anterogradely by
kinesin motors moving along MTs (microtubules), whereas
the dynein–dynactin complex mediates retrograde axonal
transport, from synapse to the cell body [2,3]. Tau is an MT-
associated protein that binds to and stabilizes MTs in axons.
This ensures MT-dependent axonal transport of vesicles and
organelles by motor proteins [4], but, upon phosphorylation,
tau affinity for MTs is reduced [5,6], leading to a decrease
in MT stability which cumulatively leads to loss of function,
aggregation of tau and formation of NFTs (neurofibrillary
tangles) [7]. Phosphorylation is sufficient to induce this
loss of function as dephosphorylation of pathological tau
by phosphatases restores the MT-stabilizing activity of tau
[8]. In addition, hyperphosphorylated and/or aggregated
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species of tau may exert direct toxic effects on neurons [9].
Hyperphosphorylated tau and paired helical filaments are a
characteristic of AD (Alzheimer’s disease) [10], as well as
some prion diseases [11]. Also, there is a reported increase in
tauprotein andphospho-tau in cerebrospinal fluid in sporadic
CJD (Creutzfeldt–Jakob disease) patients [12–14].
In animals inoculated with ME7 prion, the ensuing disease
involves an early synaptic degeneration independent of
subsequent cell loss [15]. It may be that, during disease
progression, pathological misfolded PrP (prion protein),
PrPSc (scrapie isoform of PrP), results in blockade of
axonal transport. Indeed, past studies have also suggested
a molecular interaction between tau protein and PrP [16].
Nevertheless, transgenic mice overexpressing four-repeat tau
with a reported impairment of axonal transport displayed
comparable incubation times with those in control animals
following intraneural infection with scrapie [17]. There was
also no change in the incubation time after peripheral
prion infection in mice with a heterozygous mutation
of dynein, a motor protein involved in the transport of
axonal cargo along the cytoskeleton [18]. Studies in BSE
(bovine spongiform encephalitis)-infected bovine prion
protein (Bo-PrP) transgenic animals reported an increase in
hyperphosphorylated tau [19]. Together, these studies imply
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that tau contributes directly to disease or might act as a
useful marker defining key stages in disease progression.
We have taken advantage of our observation that synapse
loss occurs relatively early in ME7 disease to investigate
whether changes in tau are implicated in this early pathology.
Using previously described protocols for Western blotting
and immunocytochemical investigation of tau [20,21], we
found data to suggest that tau is not causative in early disease
mechanism, but rather reflects aspect(s) of end-stage prion
disease pathology.
ME7 model
Before commencing analyses of tau biochemistry and
immunohistochemistry, neuropathological examination was
performed on brains used for the study described below.
This revealed spongiform changes, synaptic degeneration,
astrogliosis and abundant PrP immunoreactivity in hippo-
campal extracts and sections from ME7- when compared
with NBH- (normal brain homogenate) treated animals.
These comparisons used animals at 13 and 20 weeks
after inoculation to define relatively early and late stages
of disease (Figure 1) [20,21]. Immunostaining with 6H4
monoclonal anti-PrP antibody reveals PrPSc deposits at
the late stage of disease, anti-GFAP (glial fibrillary acid
protein) antibody staining shows large numbers of activated
astrocytes, and tomato lectin staining shows microglia with
altered morphology. Anti-synaptophysin staining depicts
increasing disorganization of synaptic architecture and
decreased expression of presynaptic marker protein in ME7-
compared with NBH-treated animals. In a similar way,
Western blot analysis of brain homogenates from ME7-
compared with NBH-treated animals revealed accumulation
of PrPSc, decreased immunoreactivity for synaptophysin
(synapse loss) and increased GFAP (astrocytosis) (results not
shown) [20–22].
Tau biochemistry
Hippocampal homogenates from NBH- and ME7-treated
animals described above were separated into detergent-
soluble and detergent-insoluble fractions by ultracentrifuga-
tion in RIPA buffer containing 1%Nonidet P40 as described
in [20]. The insoluble pellet is enriched in tau aggregates and
such insolubility is a characteristic of authentic AD-deri-
ved tau filaments [23,24]. In addition, hyperphosphorylated
tau has reduced MT binding and is released into the
soluble pool. This is associated with a destabilized MT
network and leads to deficits in the neuronal transport.
Thus investigating the proportion of various tau species
in these fractions from control and diseased brains gives
distinct biochemical correlates of dysfunctional tau. We used
a phosphorylation-independent anti-(total tau) antibody to
immunoblot detergent-soluble and detergent-insoluble tau
extracted from the hippocampus of NBH- and ME7-treated
animals at 13 and 20 weeks. Tau resolved as a band of 45–
50 kDa (Figure 2A). This pattern was identical with that
detectedwith anti-phospho-tau antibodies PHF-1 (epitope at
Figure 1 Immunohistochemical findings in ME7- compared with
NBH-treated animals
Coronal section of the dorsal hippocampus reveals widespread
PrP-immunoreactivity (6H4 immunostaining), pronounced astrogliosis
(GFAP immunostaining), evidence of microgliosis (tomato lectin
immunostaining) and synaptic degeneration (synaptophysin immunos-
taining). Scale bars, 20 µm, except for synaptophysin: 50 µm. In the
PrP-immunohistochemistry panels, note the evidence of diffuse and focal
PrP deposits. In the synaptophysin-immunostaining panels, note the loss
of discrete laminae with late-stage disease. Nuclei were counterstained
with haematoxylin. GrDG, granular layer dentate gyrus; LMol, molecular
layer; MoDG, molecular layer dentate gyrus; SPy, stratum pyramidal;
SRad, stratum radiatum.
residues 396/404),MC1, a conformation-dependent antibody
(amino acids 7–9 and 313–322), and CP13 (epitope at residue
202), which were gifts from Dr Peter Davies (Albert Einstein
College of Medicine, New York, NY, U.S.A.) (Figures 2B–
2D). The immunoblots were quantified and are presented as
normalized relative pixel intensities (Figures 2E–2H) [21,25].
Total tau content measured in both detergent-insoluble
and detergent-soluble fractions did not differ in NBH-
compared with ME7-treated animals at 13 or 20 weeks, but
we observed a higher level of detergent-soluble tau compared
with detergent-insoluble tau at 20 weeks. Phosphorylation of
C©The Authors Journal compilation C©2010 Biochemical Society
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tau as measured by three antibodies (CP13, MC1 and PHF-
1) showed no difference between NBH- and ME7-treated
animals at either time point (Figure 2E-H). However, as
with the total tau, we observed a higher level of phospho-
tau immunoreactivity in the detergent-soluble tau fractions
compared with detergent-insoluble tau at 20 weeks.
Tau histology
We immunostained coronal sections adjacent to those shown
in Figure 1 with anti-phospho-tau antibodies and revealed
numerous tau-positive cellular profiles in the hippocampus.
As a control for disease-associated hyperphosphorylated tau,
we examined the triple-transgenic AD (3×Tg-AD) mouse
model. These mice harbour the mutant genes for amyloid
precursor proteinSWE, for presenilin 1M146V and for tauP301L,
and show temporal- and region-specific tau pathology,
closely resembling that seen in the human AD brain [26]. We
found that several brain regions were tau-immunopositive in
the 3×Tg-AD animals as reported previously [26] (Figure 3,
and results not shown). In the 3×Tg-AD mice, the neurons
were intensely labelled by markers of tau pathology PHF-1,
pSer214 (epitope at residue 214 (results not shown), and in
particular pSer199−202 antibody (epitope at residues 199–202).
There is abundant pSer199/202 staining in thehippocampus and,
in the case of CA1 neuronal somata, the staining extends into
dendritic processes. This is consistent with the mis-targeting
of tau upon hyperphosphorylation, as seen in AD.
Sections from NBH- and ME7-treated animals at 13
and 20 week were treated in parallel, and comparative
staining was carried out with the same antibodies. We
observed a clear increase in the pattern and intensity of tau
accumulation in ME7- compared with NBH-treated animals
at 20 weeks (Figures 3A–3F). The NBH- and ME7-treated
animals at 13 weeks lacked these changes (results not shown),
suggesting that they were selective to late-stage pathology.
Much of the staining in ME7-treated animals is atypical
relative to tau pathology in 3×Tg-AD animals. In particular,
ME7-treated animals showed an anomalous presence of
phospho-tau-immunoreactive neuritic profiles, which were
unlike those of the 3×Tg-AD positive control (Figures 3A–
3F, arrowheads). PHF-1 antibody showed an increased
staining in ME7-treated animals relative to NBH. This
increasewas sparsely scattered inCA1andCA3and restricted
to 20 weeks (Figures 3A–3B, and results not shown). The
anti-pSer214 antibody stains primarily CA1 hippocampal
neuronal somata in ME7-treated animals (Figure 3C) and
CA3 (Figure 3D) but not in NBH-treated animals. There are
also tau-immunopositive cells in themolecular layer that may
be non-neuronal (bottom arrowhead). The anti-pSer199/202
antibody stains more scattered neurons in ME7- compared
with NBH-treated animals (Figures 3E and 3F, arrowheads).
There is some evidence of pSer199/202 staining in the neuronal
somata of NBH-treated animals at 20 weeks (Figures 3E and
3F, arrowheads), but in ME7-treated animals, the staining
is increased in the neuronal somata, neuropils and across
all hippocampal subfields and their layers, including those
relatively deficient in neuronal cell bodies (Figures 3E and 3F,
arrowheads). Overall, the pattern of immunoreactivity was
different with all anti-phospho-tau antibodies, but there was
a consistent increase in the immunohistochemically detected
phospho-tau intermediates in the ME7-infected tissue.
Tau and prion disease
Hyperphosphorylation of tau and abrogation of its physiolo-
gical function [27,28] can lead to alteration of cellular
transport of essential materials to and from the synapses
[29,30]. This altered transport may lead to progressive
degeneration initiated at the distal end of the processes
before moving retrogradely towards the cell body [31]. The
appearance of phosphorylated tau, well known in AD and
Pick’s disease, is also apparent in prion diseases [10,11]. In the
latter case, this could conceivably contribute to or be used
experimentally to highlight underlying transport deficits.
Phospho-tau deposition was assessed in detergent-soluble
and -insoluble hippocampal extracts and histologically in
hippocampal subregions using the phospho-dependent tau
antibodies. The total tau antibody revealed no differences
in the abundance of detergent-soluble and -insoluble tau
in NBH- compared with ME7-treated animals. Western
blotting using PHF-1,MC1 andCP13 (Figure 2), anti-pSer214
and anti-pSer199/202 (results not shown) antibodies revealed
that insoluble tau was phosphorylated at multiple sites in
bothNBH- andME7-treated animals at 13 and 20 weeks, but
no differences were observed between disease and control.
In contrast, immunohistology suggests that PHF-1, pSer214
and, most particularly, immunoreactivity to the pSer199/202
epitopes were more evident in ME7-treated than NBH-
treated animals at 20 weeks. Even though there was a clear
difference in the phospho-tau staining inME7-infected tissue,
it was clearly more restricted than seen in the 3×Tg-AD
tissue. Indeed, the failure to detect differences in phospho-
tau epitopes in ME7 hippocampal extracts biochemically
suggests that the changes observed are rather restricted. There
are some caveats inherent to quantification of the Western
blot data as both the MC1 and PHF-1 antibodies show
greater specificity towards pathological tau on histological
sections than in Western blots [32,33]. Also, the use of
Western blots for quantification averages in a crude mixture
of changing cell types, masking more discrete changes
revealed by immunohistochemistry. The brain regional distri-
bution of phospho-tau in ME7-treated animals paralleled the
topography of astrogliosis and PrPSc deposition observed in
these animals [21], and some of the staining associated with
ME7-infected tissue suggests that it might be associated
with non-neuronal cells. Thus the rather restricted changes
of phospho-tau staining in ME7 disease provides three
lines of evidence that suggest it is not associated with
the early synaptic dysfunction in prion disease. First, it
appears only at late time points of disease some time after
the initiation of synapse loss. Secondly, it is associated
with degenerating neurons and/or non-neuronal cells that
are reactive to neuronal loss. Thirdly, the ME7-induced
C©The Authors Journal compilation C©2010 Biochemical Society
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Figure 2 For legend see facing page
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Figure 2 Analysis of Western blots demonstrating tau phosphorylation status in detergent-extracted fractions from NBH- and
ME7-treated animals
Samples of 20 µg of detergent-soluble and detergent-insoluble extracts from the hippocampus of 13 weeks and 20 weeks
NBH- and ME7-treated animals were prepared, run on SDS/PAGE and immunoblotted with phosphorylation-independent
and phosphorylation-dependent tau antibodies. (A) total tau, (B) MC1, (C) PHF-1 and (D) CP13. Representative blots are
shown (n= 3). Total tau detected with the phosphorylation-independent tau antibody recognized a single band migrating
with an apparent molecular mass of 48–50 kDa corresponding to the band recognized by the phosphospecific antibodies.
Quantitative analysis was performed by measuring protein expression relative to the fluorescence of total protein from
individual samples stained with colloidal Coomassie Blue (E–H). Integrated intensity data in each bar are means± S.E.M.
Figure 3 Differential distribution of phospho-tau epitopes in the brains of NBH- and ME7-treated animals
Images of 10 µm adjacent coronal section from NBH- and ME7-treated animals immunostained with PHF-1, MC1, CP13,
anti-pSer214 and anti-pSer199/202 antibodies. (A and B) With the PHF-1 antibody, there was no difference in staining at
13 weeks in ME7- compared with NBH-treated animals. At 20 weeks, immunoreactive phospho-tau was localized to a distinct
somal region (arrowheads), and was more pronounced in ME7- compared with NBH-treated animals. (C and D) There were
no differences in the staining between NBH- and ME7-treated animals at 13 weeks (results not shown), but at 20 weeks,
the CP13 antibody revealed increased pSer214 staining in the ME7 tissue. Similar observations were made with the MC1
antibody (results not shown). (E and F) Some neuronal perikarya were detected by anti-phospho-tau antibody pSer199−202,
indicating pre-tangle-like structures in the hippocampus. This was restricted to 20 weeks and was more pronounced in ME7-
compared with NBH-treated animals at 20 weeks. (G, H) Sections from 12-month old 3×Tg-AD mice were included as
positive controls as these animals have substantial tau pathology. Note the pronounced dendritic staining (arrowhead) with
the anti-pSer199/202 antibody. Scale bar, 20 µm. LMol, molecular layer; SPy, stratum pyramidal; SRad, stratum radiatum.
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phospho-tau immunoreactivity is not associated with the
neuronal compartments (axons or dendrites) that might
express dysfunctional transport to drive a synaptic loss.
Nevertheless, increased phospho-tau immunoreactivity
(PHF-1, pSer214, pSer199/202) in ME7- compared with NBH-
treated animals is consistent with studies in BSE-infected
Bo-PrP transgenic animals where increased hyperphos-
phorylated tau is reported [19]. It is also in accordwith reports
of an increase in CSF (cerebrospinal fluid) phospho-tau
levels associated with sporadic CJD [13,34], studies in human
vCJD (variant CJD) and experimental mouse models that
showed diffuse phospho-tau-positive neurites and perikarya,
associated with PrP amyloid [35]. Consistent with this,
accumulations of hyperphosphorylated tau, identical with
that in AD, have been described coincident with PrPSc
deposits in GSS (Gerstmann–Stra¨ussler–Scheinker) disease
[36]. Dystrophic tau-immunoreactive neurites were also
observed associated with PrP deposits in very old mice with
advanced scrapie infection [37]. Taken together, our data
suggest that modest changes in tau metabolism are associated
with late-stage disease, but argue against its use as a causative
pathway or indeed a useful marker in the early processes that
give rise to the synaptopathy associated with disease. This
still leaves unresolved the potential role of axonal transport
deficits as important determinants in the early stages of prion
disease.
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